Skip to main content
UniHealth

Doctor search

Sandhya Srinivas, MD

Medical Oncology · Stanford

NPI 1205913589

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
17
3 carriers
Office
1
Since medical school
41 years
Graduated 1985

Offices

1 location · Stanford Health Care · 3,152 clinicians in this group

Looking this up.

Hospitals listed: Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.

Plans that list them

17 plans · 3 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Srinivas’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

17 of 17 plans

Plans whose provider directory lists this clinician
Alignment Health BreathEasy (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Clarity (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Harmony (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Honor+ Plan (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health My Choice CalCare (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Silicon (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health smartHMO (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health the ONE (HMO)Alignment Health PlanListedOct 3, 2026
SCAN Balance (HMO C-SNP)SCAN Health PlanListedOct 3, 2026
SCAN Classic (HMO)SCAN Health PlanListedOct 3, 2026
SCAN MyChoice (HMO)SCAN Health PlanListedOct 3, 2026
SCAN Strive (HMO C-SNP)SCAN Health PlanListedOct 3, 2026
DualConnect (HMO D-SNP)Santa Clara Family Health PlanListedSep 1, 2026

California Medical Board record

Licence A49392 · Current

Licensed to practise in California · since 1991 · expires 2027-03-31 · University of Madras, Madras Medical College.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

School, training and certification

What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.

Specialty certification

  • American Board of Internal Medicine - Medical Oncology

Hospitals they work in

2 hospitals

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend it
    Overall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
  • Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend it
    Overall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths5.31 (4.24 to 6.37) · 8,661 casesWorseJul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits14.1 (12.7 to 15.7) · 2,191 casesWorseJan 2024 – Dec 2024
Postoperative respiratory failure rateComplications and deaths4.08 (1.95 to 6.21) · 5,296 casesBetterJul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.317BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.446BetterOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0.241BetterOct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.7 (0.6 to 0.9) · 3,348 casesBetterJan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.06 (0.45 to 1.67) · 5,374 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.86 (0.72 to 1)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths166.09 (137.88 to 194.3) · 470 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.1 · 192 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths6.4 · 146 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths9.7 · 253 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths6.3 · 880 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 935 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths8.7 · 501 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.1 · 7,730 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.13 (0 to 0.27) · 20,799 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.28 (0.14 to 0.43) · 23,182 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths0.94 (0.2 to 1.68) · 5,694 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.36 (1.54 to 3.19) · 7,846 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.2 (3.76 to 6.64) · 5,603 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.38 (0.23 to 2.53) · 2,211 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.52 (0.21 to 0.83) · 19,915 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths3.6 · 416 casesNoneApr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.869No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.857No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections0.368No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits16.2 · 247 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.5 · 1,021 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits47.8 · 258 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-1.6 · 990 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits20.8 · 976 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.5 · 959 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.2 (4.4 to 6.2) · 2,191 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.1 · 425 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits9.6 · 158 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.6 · 183 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.7 (10.4 to 15.4) · 4,578 casesNo differentJan 2022 – Dec 2024

What patients said (6,810 patients answered, 25% of those asked)

Patient survey stars by topic at Stanford Health Care
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness2
Recommend hospital5
Share of patients giving the best answer at Stanford Health Care
Room was "always" clean75%
Nurses "always" communicated well82%
Doctors "always" communicated well81%
Staff "always" explained63%
Yes, staff "did" give patients this information89%
Yes, staff "did" give patients information about help after discharge89%
Doctors "always" explained things so they could understand76%
Doctors "always" listened carefully80%
Doctors "always" treated them with courtesy and respect87%
Patients who gave a rating of "9" or "10" (high)79%
Staff "always" explained new medications76%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully79%
Nurses "always" treated them with courtesy and respect88%
"Always" quiet at night53%
"YES", patients would definitely recommend the hospital83%
Staff "always" explained possible side effects50%
Yes, staff "did" give patients information about possible symptoms90%
See every measure and the patient survey for Stanford Health Care Tri-Valley

Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care Tri-Valley
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.178BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.237BetterOct 2024 – Sep 2025
Abdominopelvic accidental puncture or laceration rateComplications and deaths0.79 (0 to 1.73) · 1,041 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.79 (0.5 to 1.08)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths145.81 (96.5 to 195.12) · 72 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths2.9 · 55 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths8.6 · 92 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths12.5 · 96 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths9.5 · 395 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 391 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths10.1 · 162 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths3 · 1,736 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.16 (0 to 0.37) · 4,425 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.22 (0.02 to 0.41) · 4,771 casesNo differentJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths3.45 (1.46 to 5.44) · 1,403 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths1.5 (0.05 to 2.94) · 645 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths1.81 (0.38 to 3.24) · 1,279 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths8.53 (3.2 to 13.85) · 639 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.15 (1.89 to 8.41) · 648 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.61 (0.14 to 3.07) · 370 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.16 (0 to 0.83) · 4,160 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths4 · 74 casesNoneApr 2023 – Mar 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.369No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections1.112No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits13.1 · 110 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.1 · 437 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits-5.8 · 94 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-19.3 · 456 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits-0.3 · 402 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits15.8 · 358 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits6.8 (4.7 to 9.6) · 198 casesNo differentJan 2024 – Dec 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits10.1 (7.5 to 13.6) · 198 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.3 · 80 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits10.9 · 46 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.3 · 92 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.4 (9.6 to 16.2) · 1,532 casesNo differentJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits1 (0.8 to 1.2) · 929 casesNo differentJan 2024 – Dec 2024

What patients said (1,268 patients answered, 26% of those asked)

Patient survey stars by topic at Stanford Health Care Tri-Valley
Cleanliness3
Nurse communication3
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating3
Quietness2
Recommend hospital4
Share of patients giving the best answer at Stanford Health Care Tri-Valley
Room was "always" clean65%
Nurses "always" communicated well77%
Doctors "always" communicated well79%
Staff "always" explained58%
Yes, staff "did" give patients this information88%
Yes, staff "did" give patients information about help after discharge88%
Doctors "always" explained things so they could understand74%
Doctors "always" listened carefully78%
Doctors "always" treated them with courtesy and respect86%
Patients who gave a rating of "9" or "10" (high)70%
Staff "always" explained new medications72%
Nurses "always" explained things so they could understand73%
Nurses "always" listened carefully74%
Nurses "always" treated them with courtesy and respect84%
"Always" quiet at night42%
"YES", patients would definitely recommend the hospital74%
Staff "always" explained possible side effects44%
Yes, staff "did" give patients information about possible symptoms89%

Original Medicare doctor bills

$120,156

Medicare paid this office $120,156 for 372 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Return visit (30+ min)269$70,823$116
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes33$12,875$106
Return visit (30+ min)69$9,585$79
New patient visit (45+ min)58$8,455$146
Long return visit (40+ min)34$6,846$171
See all 10 services
Every Original Medicare service billed
Return visit (30+ min)269$70,823$116
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes33$12,875$106
Return visit (30+ min)69$9,585$79
New patient visit (45+ min)58$8,455$146
Long return visit (40+ min)34$6,846$171
Initial hospital care with moderate level of medical decision making at least 75 minutes23$3,871$155
New patient visit (60+ min)11$2,295$209
New patient visit (45+ min)23$2,276$99
Long return visit (40+ min)11$1,559$130
Hospital discharge day management, 30 minutes or less13$962$74

Who their Medicare patients are

372 Original Medicare patients in 2024. Average age 76 · Under 65 5% · 85 and older 14% · Women 22% · Also on Medicaid 17% · Health risk score 2.20. Above the middle of the specialty; the typical medical oncology clinician is at 2.11.

Conditions among them: Cancer 75% · High blood pressure 72% · Chronic kidney disease 38% · Coronary heart disease 33% · Diabetes 28% · Heart failure 19% · Atrial fibrillation 18% · Depression 15% · COPD 9% · Stroke 9% · Dementia 5%.

The office billed $652,893, Medicare allowed $158,711 and paid $120,156; for 1,041 services of 11 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
20243721,041762.20$652,893$120,156
20233591,066752.21$609,552$98,262
20223681,217752.04$667,706$112,058
20213801,223762.54$636,897$106,116
2020313994752.33$352,060$74,318
2019314869752.19$138,928$68,705
2018312800742.32$144,291$64,867
2017302740752.33$157,120$57,352
2016338845742.31$202,137$64,952
2015365930732.16$230,760$71,826
2014315999742.06$216,575$70,481
20133561,188742.10$267,968$82,972

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 5 services

Original Medicare services billed in 2023
Return visit (30+ min)259$60,337$84
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes44$20,075$110
New patient visit (45+ min)80$9,213$115
Initial hospital care with moderate level of medical decision making at least 75 minutes26$4,158$160
Hospital discharge day management, 30 minutes or less31$2,505$76

2022: 8 services

Original Medicare services billed in 2022
Return visit (30+ min)186$35,364$87
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes61$27,388$93
Long return visit (40+ min)88$15,242$130
Short return visit (20+ min)141$10,767$52
New patient visit (45+ min)76$9,134$120
Initial hospital care with moderate level of medical decision making at least 75 minutes41$7,655$182
Hospital discharge day management, 30 minutes or less33$2,265$67
Hospital discharge day management, more than 30 minutes11$1,080$98

2021: 9 services

Original Medicare services billed in 2021
Return visit (30+ min)182$32,891$85
Short return visit (20+ min)196$23,549$59
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes59$17,448$95
Long return visit (40+ min)59$10,294$137
Initial hospital care with moderate level of medical decision making at least 75 minutes46$8,360$182
New patient visit (45+ min)51$6,383$125
Hospital discharge day management, more than 30 minutes15$1,501$100
Hospital discharge day management, 30 minutes or less18$1,257$70
New patient visit (30+ min)16$1,211$76

2020: 5 services

Original Medicare services billed in 2020
Return visit (30+ min)238$50,896$68
New patient visit (45+ min)77$8,932$116
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes12$5,282$98
Return visit (30+ min)45$3,643$74
Telehealth originating site facility fee14$298$21

2019: 5 services

Original Medicare services billed in 2019
Return visit (30+ min)216$41,341$67
New patient visit (45+ min)97$11,033$114
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes30$8,207$94
Initial hospital care with moderate level of medical decision making at least 75 minutes26$4,956$184
Hospital discharge day management, 30 minutes or less17$1,148$68

2018: 5 services

Original Medicare services billed in 2018
Return visit (30+ min)198$32,711$67
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes39$13,575$94
New patient visit (45+ min)73$8,047$110
Initial hospital care with moderate level of medical decision making at least 75 minutes28$5,094$182
Long return visit (40+ min)15$1,496$94

2017: 3 services

Original Medicare services billed in 2017
Return visit (30+ min)193$34,174$67
New patient visit (45+ min)89$10,026$113
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes24$7,572$93

2016: 5 services

Original Medicare services billed in 2016
Return visit (30+ min)225$38,803$66
New patient visit (45+ min)95$10,682$112
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes25$8,055$93
Initial hospital care with moderate level of medical decision making at least 75 minutes19$3,605$180
Long return visit (40+ min)11$991$90

2015: 4 services

Original Medicare services billed in 2015
Return visit (30+ min)229$39,349$64
New patient visit (45+ min)119$12,914$109
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes38$11,437$93
Initial hospital care with moderate level of medical decision making at least 75 minutes28$5,059$181

2014: 2 services

Original Medicare services billed in 2014
Return visit (30+ min)254$54,089$65
New patient visit (45+ min)95$10,752$113

2013: 4 services

Original Medicare services billed in 2013
Return visit (30+ min)279$62,734$63
New patient visit (45+ min)100$10,724$107
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes21$5,991$89
Initial hospital care with moderate level of medical decision making at least 75 minutes12$2,268$174

Medicaid work

$8,500 in 2024

Medicaid paid $8,500 for 140 billed services this clinician did in 2024, up to 22 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Largest Medicaid services in 2024
Return visit (30+ min)107$5,799
SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES33$2,701
Medicaid work by year
2024140222$8,500
2023386328$15,222
2022240125$9,591
2021143317$4,023
202090120$2,569
2019137219$5,637
201839112$1,815
See the largest Medicaid services in earlier years

2023

Largest Medicaid services in 2023
Return visit (30+ min)306$12,207
SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES50$1,532
Long return visit (40+ min)30$1,483

2022

Largest Medicaid services in 2022
Return visit (30+ min)240$9,591

2021

Largest Medicaid services in 2021
Return visit (30+ min)68$2,305
SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES35$1,089
Short return visit (20+ min)40$629

2020

Largest Medicaid services in 2020
Return visit (30+ min)90$2,569

2019

Largest Medicaid services in 2019
Return visit (30+ min)92$3,158
SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES45$2,479

2018

Largest Medicaid services in 2018
SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES39$1,815

Drugs they prescribed that Part D paid

$723,334

Pharmacies billed $723,334 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

173 generic and fewer than 11 brand-name prescriptions · $723,334 in drug cost.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Largest Part D drug costs
Cabometyx15$352,088$23,473
Abiraterone Acetate19$13,622$717
Bicalutamide18$657$36
Dexamethasone20$215$11
Prednisone31$211$7
See all 6 drugs
Every Part D drug this clinician prescribed
Cabometyx15$352,088$23,473
Abiraterone Acetate19$13,622$717
Bicalutamide18$657$36
Dexamethasone20$215$11
Prednisone31$211$7
Ondansetron15$55$4

Year by year

Part D prescribing by year
202422163NoneNone$723,334
2023259754% (11)None$680,501
2022269848% (21)None$583,039
2021200637% (13)17%$442,347
2020250634% (11)None$976,161
2019365856% (22)42%$1,471,180
2018308784% (12)None$1,386,582
201728971None44%$1,152,765
201633280None37%$962,942
2015600128NoneNone$1,760,774
2014733119None42%$2,181,395
20137421316% (41)33%$1,278,516

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 4 drugs

Part D drugs prescribed in 2023
Abiraterone Acetate15$17,506$1,167
Prednisone58$444$8
Ondansetron16$148$9
Dexamethasone11$131$12

2022: 6 drugs

Part D drugs prescribed in 2022
Cabometyx11$275,584$25,053
Abiraterone Acetate23$116,647$5,072
Prednisone48$481$10
Levothyroxine20$229$11
Ondansetron15$199$13
Dexamethasone14$172$12

2021: 4 drugs

Part D drugs prescribed in 2021
Xtandi13$166,495$12,807
Abiraterone Acetate26$96,666$3,718
Bicalutamide14$650$46
Prednisone46$446$10

2020: 4 drugs

Part D drugs prescribed in 2020
Xtandi31$346,369$11,173
Zytiga17$193,617$11,389
Abiraterone Acetate16$45,983$2,874
Prednisone44$462$11

2019: 8 drugs

Part D drugs prescribed in 2019
Zytiga45$471,556$10,479
Xtandi38$420,134$11,056
Afinitor14$230,174$16,441
Abiraterone Acetate16$56,202$3,513
Eliquis15$7,578$505
Prednisone55$545$10
Dexamethasone13$235$18
Ondansetron13$144$11

2018: 5 drugs

Part D drugs prescribed in 2018
Xtandi51$554,053$10,864
Zytiga25$251,048$10,042
Inlyta21$224,881$10,709
Votrient11$135,530$12,321
Prednisone25$228$9

2017: 7 drugs

Part D drugs prescribed in 2017
Xtandi57$536,435$9,411
Votrient22$241,989$11,000
Zytiga17$165,776$9,752
Inlyta12$146,480$12,207
Bicalutamide24$481$20
Prednisone25$174$7
Tamsulosin13$151$12

2016: 9 drugs

Part D drugs prescribed in 2016
Xtandi54$487,034$9,019
Votrient14$105,515$7,537
Zytiga12$105,341$8,778
Tamsulosin17$640$38
Bicalutamide25$526$21
Dexamethasone16$228$14
Prednisone21$188$9
Ondansetron13$135$10
Prochlorperazine Maleate20$113$6

2015: 15 drugs

Part D drugs prescribed in 2015
Xtandi83$726,368$8,751
Zytiga53$423,470$7,990
Inlyta27$250,433$9,275
Votrient24$170,469$7,103
Sutent13$95,830$7,372
Bicalutamide40$1,090$27
Hydrocortisone13$581$45
Tamsulosin11$534$49
Prednisone55$462$8
Ondansetron15$309$21
Megestrol Acetate12$187$16
Dexamethasone15$138$9
Alendronate15$111$7
Prochlorperazine Maleate11$66$6
Lorazepam12$28$2

2014: 16 drugs

Part D drugs prescribed in 2014
Zytiga84$633,775$7,545
Inlyta49$487,256$9,944
Xtandi52$425,575$8,184
Votrient32$249,427$7,795
Sutent23$130,192$5,661
Bicalutamide71$2,667$38
Hydrocortisone17$1,048$62
Prednisone80$796$10
Nystatin17$720$42
Ondansetron26$493$19
Potassium Chloride13$348$27
Megestrol Acetate13$290$22
Levothyroxine23$275$12
Gabapentin12$206$17
Lisinopril28$142$5
Prochlorperazine Maleate17$122$7

2013: 21 drugs

Part D drugs prescribed in 2013
Zytiga71$403,774$5,687
Votrient45$323,994$7,200
Inlyta13$121,324$9,333
Afinitor12$106,834$8,903
Xtandi13$99,679$7,668
Nilandron25$80,024$3,201
Emend20$6,693$335
Bicalutamide57$3,679$65
Hydrocortisone27$1,163$43
Dexamethasone14$1,002$72
Megestrol Acetate15$884$59
Ketoconazole12$831$69
Tamsulosin11$684$62
Nystatin12$524$44
Ondansetron19$435$23
Prednisone65$373$6
Alendronate38$367$10
Hydrocodone-Acetaminophen15$258$17
Prochlorperazine Maleate25$176$7
Lorazepam27$147$5
Levothyroxine11$132$12

Money from drug and device companies

$14,497 in 2025

Industry payments by year
20251123$12,670$14,497
2024724$13,631$36,119
20231019$19,361$20,843
20221227$30,379$31,265
20211020$36,654$36,785
2020923$25,587$26,151
2019967$44,097$53,854

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
Janssen BiotechErleada$4,230
2 payments
  • Consulting for Erleada · 2025-06-13 · $1,763
  • Consulting · 2025-02-28 · $2,468
Merck Sharp & DohmeNone$3,103
9 payments
  • Consulting · 2025-07-23 · $2,240
  • Travel · 2025-04-23 · $43
  • Meals · 2025-04-09 · $65
  • Meals · 2025-04-09 · $15
  • Meals · 2025-04-09 · $35
  • Travel · 2025-04-08 · $259
  • Travel · 2025-04-08 · $156
  • Travel · 2025-04-08 · $205
  • Meals · 2025-04-08 · $85
Janssen Research & DevelopmentNone$2,300
1 payment
  • Consulting · 2025-10-02 · $2,300
Astellas Pharma Global DevelopmentXtandi$2,100
1 payment
  • Consulting for Xtandi · 2025-12-12 · $2,100
Janssen Scientific AffairsErleada$1,918
2 payments
  • Consulting for Erleada · 2025-06-18 · $1,800
  • Meals for Erleada · 2025-06-03 · $118
Aveo PharmaceuticalsFotivda$268
2 payments
  • Meals for Fotivda · 2025-11-20 · $151
  • Meals for Fotivda · 2025-06-01 · $117
See all 23 published payments
Every published payment
Astellas Pharma Global DevelopmentConsulting · 2025-12-12Xtandi$2,100
E.R. Squibb & Sons L.L.C.Meals · 2025-12-04Opdivo$32
Aveo PharmaceuticalsMeals · 2025-11-20Fotivda$151
Astellas Pharma USMeals · 2025-11-20Xtandi$126
PfizerMeals · 2025-10-29Xtandi$27
Janssen Research & DevelopmentConsulting · 2025-10-02None$2,300
Merck Sharp & DohmeConsulting · 2025-07-23None$2,240
Caris MPIMeals · 2025-07-10Mi Cancer Seek$69
Janssen Scientific AffairsConsulting · 2025-06-18Erleada$1,800
Janssen BiotechConsulting · 2025-06-13Erleada$1,763
Janssen Scientific AffairsMeals · 2025-06-03Erleada$118
Aveo PharmaceuticalsMeals · 2025-06-01Fotivda$117
ExelixisMeals · 2025-05-31Cabometyx$175
Merck Sharp & DohmeTravel · 2025-04-23None$43
Merck Sharp & DohmeMeals · 2025-04-09None$65
Merck Sharp & DohmeMeals · 2025-04-09None$15
Merck Sharp & DohmeMeals · 2025-04-09None$35
Merck Sharp & DohmeTravel · 2025-04-08None$259
Merck Sharp & DohmeTravel · 2025-04-08None$156
Merck Sharp & DohmeTravel · 2025-04-08None$205
Merck Sharp & DohmeMeals · 2025-04-08None$85
Janssen BiotechConsulting · 2025-02-28None$2,468
PfizerMeals · 2025-02-14None$149
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)

2024: $36,119

Payments by company in 2024
Ge HealthcareNone$18,965
7 payments
  • Consulting · 2024-11-06 · $500
  • Consulting · 2024-11-06 · $500
  • Meals · 2024-09-11 · $82
  • Travel · 2024-06-18 · $17,000
  • Travel · 2024-06-01 · $631
  • Travel · 2024-06-01 · $165
  • Travel · 2024-06-01 · $87
Telix PharmaceuticalsIlluccix$5,445
9 payments
  • Consulting for Illuccix · 2024-11-21 · $1,300
  • Consulting for Illuccix · 2024-11-21 · $2,600
  • Meals for Illuccix · 2024-09-21 · $73
  • Meals for Illuccix · 2024-09-21 · $102
  • Meals for Illuccix · 2024-09-21 · $105
  • Meals for Illuccix · 2024-09-20 · $169
  • Travel for Illuccix · 2024-09-20 · $399
  • Travel for Illuccix · 2024-09-20 · $166
  • Travel for Illuccix · 2024-08-29 · $531
Eli Lilly andNone$4,500
1 payment
  • Consulting · 2024-10-14 · $4,500
Novartis PharmaceuticalsNone$3,039
4 payments
  • Travel · 2024-06-01 · $581
  • Meals · 2024-06-01 · $135
  • Consulting · 2024-06-01 · $323
  • Consulting · 2024-06-01 · $2,000
Janssen Scientific AffairsNone$2,227
1 payment
  • Travel · 2024-02-07 · $2,227
PfizerNone$1,908
1 payment
  • Consulting · 2024-11-08 · $1,908
Aveo PharmaceuticalsFotivda$34
1 payment
  • Meals for Fotivda · 2024-12-05 · $34

2023: $20,843

Payments by company in 2023
Novartis PharmaceuticalsPluvicto$5,392
2 payments
  • Consulting for Pluvicto · 2023-02-15 · $5,300
  • Meals for Pluvicto · 2023-02-15 · $92
Eli Lilly andNone$3,600
1 payment
  • Consulting · 2023-10-18 · $3,600
SeagenPadcev$3,244
3 payments
  • Consulting for Padcev · 2023-06-16 · $3,125
  • Meals for Padcev · 2023-06-02 · $60
  • Meals for Padcev · 2023-06-02 · $59
PfizerNone$3,124
4 payments
  • Consulting · 2023-11-03 · $1,908
  • Meals · 2023-06-02 · $127
  • Meals · 2023-02-16 · $135
  • Consulting · 2023-01-19 · $954
EisaiLenvima$2,401
2 payments
  • Consulting for Lenvima · 2023-06-26 · $2,280
  • Meals for Lenvima · 2023-06-05 · $121
Janssen Scientific AffairsNone$2,296
2 payments
  • Consulting · 2023-03-01 · $2,194
  • Meals · 2023-02-17 · $102
AVEO PharmaceuticalsFotivda$284
2 payments
  • Meals for Fotivda · 2023-08-26 · $46
  • Meals for Fotivda · 2023-06-01 · $238
Galvanize TherapeuticsAliya System$221
1 payment
  • Meals for Aliya System · 2023-06-22 · $221
ExelixisCabometyx$162
1 payment
  • Meals for Cabometyx · 2023-06-03 · $162
Telix PharmaceuticalsIlluccix$119
1 payment
  • Meals for Illuccix · 2023-02-16 · $119

2022: $31,265

Payments by company in 2022
Eli Lilly andNone$7,200
1 payment
  • Consulting · 2022-09-01 · $7,200
Merck Sharp & DohmeLynparza$6,450
7 payments
  • Consulting · 2022-09-28 · $1,830
  • Consulting · 2022-06-13 · $2,135
  • Meals for Lynparza · 2022-06-06 · $138
  • Consulting · 2022-03-01 · $2,135
  • Meals for Lynparza · 2022-02-19 · $148
  • Meals for Lynparza · 2022-02-19 · $29
  • Meals for Welireg · 2022-02-08 · $35
Johnson & Johnson Health Care SystemsNone$3,500
3 payments
  • Consulting · 2022-12-23 · $1,000
  • Consulting · 2022-12-23 · $1,000
  • Consulting · 2022-11-04 · $1,500
BeiGene USANone$3,500
2 payments
  • Consulting · 2022-08-24 · $2,000
  • Consulting · 2022-05-18 · $1,500
SeagenPadcev$3,184
4 payments
  • Consulting for Padcev · 2022-06-24 · $2,930
  • Meals for Padcev · 2022-06-03 · $65
  • Meals for Padcev · 2022-06-03 · $62
  • Meals · 2022-02-17 · $127
AVEO PharmaceuticalsFotivda$2,931
3 payments
  • Honoraria for Fotivda · 2022-11-01 · $2,800
  • Meals for Fotivda · 2022-06-04 · $58
  • Entertainment for Fotivda · 2022-06-03 · $73
AstraZeneca Pharmaceuticals LPLynparza$1,353
2 payments
  • Consulting for Lynparza · 2022-11-28 · $1,330
  • Meals for Lynparza · 2022-11-11 · $23
Jazz PharmaceuticalsNone$1,240
1 payment
  • Consulting · 2022-11-18 · $1,240
PfizerNone$954
1 payment
  • Consulting · 2022-04-15 · $954
Janssen Scientific AffairsErleada$825
1 payment
  • Consulting for Erleada · 2022-11-09 · $825
Progenics PharmaceuticalsPylarify$94
1 payment
  • Meals for Pylarify · 2022-11-12 · $94
Astellas Pharma USPadcev$34
1 payment
  • Meals for Padcev · 2022-12-01 · $34

2021: $36,785

Payments by company in 2021
PfizerNone$8,673
5 payments
  • Consulting · 2021-11-17 · $954
  • Honoraria · 2021-10-05 · $2,100
  • Honoraria · 2021-06-08 · $1,665
  • Consulting · 2021-02-12 · $954
  • Honoraria · 2021-02-09 · $3,000
Merck Sharp & DohmeKeytruda$6,707
4 payments
  • Consulting · 2021-12-03 · $2,440
  • Consulting · 2021-07-01 · $2,000
  • Meals for Keytruda · 2021-05-20 · $17
  • Consulting · 2021-03-24 · $2,250
EisaiLenvima$5,313
3 payments
  • Consulting for Lenvima · 2021-09-24 · $1,875
  • Consulting for Lenvima · 2021-04-20 · $1,875
  • Consulting for Lenvima · 2021-02-18 · $1,563
Bayer HealthCare PharmaceuticalsXofigo$5,264
1 payment
  • Consulting for Xofigo · 2021-05-07 · $5,264
Novartis PharmaceuticalsNone$3,144
1 payment
  • Consulting · 2021-06-14 · $3,144
Hra Pharma Rare DiseasesLysodren$2,000
1 payment
  • Consulting for Lysodren · 2021-11-08 · $2,000
SeagenPadcev$1,975
2 payments
  • Meals · 2021-06-23 · $115
  • Consulting for Padcev · 2021-03-19 · $1,860
Aveo PharmaceuticalsFotivda$1,400
1 payment
  • Honoraria for Fotivda · 2021-12-09 · $1,400
E.R. Squibb & Sons L.L.C.None$1,300
1 payment
  • Consulting · 2021-11-19 · $1,300
Janssen Scientific AffairsErleada$1,010
1 payment
  • Consulting for Erleada · 2021-09-01 · $1,010

2020: $26,151

Payments by company in 2020
Bayer HealthCare PharmaceuticalsNubeqa$6,337
5 payments
  • Consulting for Nubeqa · 2020-08-25 · $2,106
  • Meals for Nubeqa · 2020-02-14 · $27
  • Consulting for Nubeqa · 2020-02-14 · $2,800
  • Meals for Nubeqa · 2020-02-14 · $98
  • Consulting for Nubeqa · 2020-01-16 · $1,306
E.R. Squibb & Sons L.L.C.Opdivo$4,388
2 payments
  • Consulting for Opdivo · 2020-11-12 · $1,625
  • Consulting for Opdivo · 2020-07-14 · $2,763
EisaiLenvima$3,591
5 payments
  • Consulting for Lenvima · 2020-08-20 · $1,563
  • Education for Lenvima · 2020-02-19 · $13
  • Meals for Lenvima · 2020-02-15 · $117
  • Consulting for Lenvima · 2020-02-15 · $1,875
  • Meals for Lenvima · 2020-02-15 · $23
PfizerBavencio$3,578
2 payments
  • Consulting · 2020-12-24 · $1,193
  • Consulting for Bavencio · 2020-01-02 · $2,385
ExelixisCabometyx$2,227
4 payments
  • Paid to speak or teach for Cabometyx · 2020-02-12 · $1,980
  • Meals for Cabometyx · 2020-02-12 · $46
  • Meals for Cabometyx · 2020-02-12 · $157
  • Travel for Cabometyx · 2020-02-12 · $45
SeagenPadcev$2,034
2 payments
  • Consulting · 2020-08-26 · $1,995
  • Meals for Padcev · 2020-02-14 · $39
HRA Pharma Rare DiseasesLysodren$1,500
1 payment
  • Consulting for Lysodren · 2020-11-18 · $1,500
Merck Sharp & DohmeNone$1,500
1 payment
  • Consulting · 2020-10-23 · $1,500
AstraZeneca Pharmaceuticals LPLynparza$998
1 payment
  • Consulting for Lynparza · 2020-10-07 · $998

2019: $53,854

Payments by company in 2019
EisaiLenvima$12,683
16 payments
  • Consulting for Lenvima · 2019-12-06 · $1,250
  • Travel for Lenvima · 2019-07-11 · $65
  • Travel for Lenvima · 2019-07-11 · $448
  • Meals for Lenvima · 2019-07-11 · $37
  • Consulting for Lenvima · 2019-07-11 · $5,250
  • Travel for Lenvima · 2019-07-11 · $281
  • Travel for Lenvima · 2019-07-11 · $36
  • Meals for Lenvima · 2019-07-11 · $22
  • Meals for Lenvima · 2019-07-11 · $50
  • Meals for Lenvima · 2019-07-11 · $24
  • Consulting for Lenvima · 2019-02-17 · $3,438
  • Travel for Lenvima · 2019-02-17 · $413
  • Meals for Lenvima · 2019-02-17 · $48
  • Meals for Lenvima · 2019-02-17 · $24
  • Consulting for Lenvima · 2019-02-17 · $1,250
  • Meals for Lenvima · 2019-02-17 · $48
PfizerBavencio$9,396
6 payments
  • Travel for Talzenna · 2019-11-27 · $111
  • Meals · 2019-10-24 · $459
  • Travel · 2019-10-24 · $256
  • Travel · 2019-10-24 · $277
  • Travel · 2019-10-24 · $303
  • Consulting for Bavencio · 2019-03-20 · $7,990
Bayer HealthCare PharmaceuticalsNon-Covered$8,460
14 payments
  • Meals for Nubeqa · 2019-11-15 · $30
  • Meals for Non-Covered · 2019-04-06 · $54
  • Travel for Non-Covered · 2019-04-06 · $49
  • Travel for Non-Covered · 2019-04-06 · $160
  • Meals for Non-Covered · 2019-04-06 · $47
  • Consulting for Non-Covered · 2019-04-06 · $4,250
  • Travel for Non-Covered · 2019-04-06 · $72
  • Meals for Non-Covered · 2019-04-06 · $23
  • Meals for Non-Covered · 2019-04-06 · $24
  • Travel for Non-Covered · 2019-04-06 · $3
  • Travel for Non-Covered · 2019-04-05 · $125
  • Travel for Non-Covered · 2019-03-13 · $518
  • Consulting for Non-Covered · 2019-02-14 · $1,680
  • Consulting for Non-Covered · 2019-01-10 · $1,425
Merck Sharp & DohmeNone$6,738
8 payments
  • Travel · 2019-12-18 · $150
  • Consulting · 2019-12-18 · $5,500
  • Travel · 2019-12-13 · $238
  • Meals · 2019-12-13 · $55
  • Meals · 2019-12-13 · $60
  • Meals · 2019-12-13 · $65
  • Travel · 2019-12-12 · $232
  • Travel · 2019-12-12 · $438
Janssen BiotechBalversa$6,677
10 payments
  • Travel for Balversa · 2019-08-28 · $42
  • Consulting for Balversa · 2019-07-12 · $2,778
  • Travel for Balversa · 2019-06-21 · $1,310
  • Meals for Balversa · 2019-06-21 · $26
  • Meals for Balversa · 2019-06-21 · $43
  • Meals for Balversa · 2019-06-21 · $30
  • Meals for Darzalex · 2019-05-31 · $100
  • Consulting · 2019-02-22 · $2,200
  • Meals · 2019-02-12 · $125
  • Meals · 2019-02-12 · $23
GenentechTecentriq$5,638
6 payments
  • Meals for Tecentriq · 2019-09-07 · $402
  • Travel for Tecentriq · 2019-09-06 · $165
  • Travel for Tecentriq · 2019-09-06 · $534
  • Meals for Tecentriq · 2019-09-06 · $114
  • Consulting for Tecentriq · 2019-09-06 · $3,500
  • Travel for Tecentriq · 2019-09-06 · $923
Janssen Scientific AffairsErleada$2,495
3 payments
  • Consulting for Erleada · 2019-02-21 · $2,060
  • Meals for Erleada · 2019-02-21 · $125
  • Travel for Erleada · 2019-02-21 · $310
Genentech USANon-Covered Product$1,231
3 payments
  • Consulting for Non-Covered Product · 2019-11-19 · $990
  • Meals for Avastin · 2019-06-01 · $127
  • Meals for Tecentriq · 2019-02-15 · $114
AstraZeneca Pharmaceuticals LPImfinzi$537
1 payment
  • Consulting for Imfinzi · 2019-01-16 · $537

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
Merck Sharp & Dohme LLC · A Multi-Center, Double-Blind, Randomized Phase 3 Study To Compare the Efficacy and Safety of Belzutifan Mk-6482 Plus Pembrolizumab Mk- 3475 Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma Ccrcc Post Nephrectomy 6482-022 · 2023Their institution$485,076
Regeneron Pharmaceuticals, Inc. · Phase 1/2 Study of Regn4336 (A Psmaxcd3 Bispecific Antibody) Administered Alone Or in Combination With Cemiplimab in Patients With Metastatic Castration-Resistant Prostate Cancer · 2025Their institution$461,431
Celgene Corporation · Ph I Fih Mcrpc Mono Cc-94676-Pca-001 - A Phase 1, Multi-Center, Open-Label, Dose Finding Study To Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Cc-94676 in Subjects With Metastatic Castration-Resistant Prostate Cancer · 2023Their institution$455,555
Merck Sharp & Dohme LLC · A Multicenter, Double-Blind, Randomized Phase 3 Study To Compare the Efficacy and Safety of Belzutifan Mk-6482 Plus Pembrolizumab Mk-3475 Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma Ccrcc Post Nephrectomy Mk-6482-022 · 2024Their institution$410,802
Merck Sharp & Dohme Corporation · A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab Mk-3475 As Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy · 2019Their institution$409,436
Exelixis Inc. · Study of Cabozantinib in Combination With Atezolizumab To Subjects With Locally Advanced Or Metastatic Solid Tumors · 2020Their institution$356,846
Merck Sharp & Dohme LLC · A Phase 3, Randomized, Open-Label Study To Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab Mk-3475 Versus Neoadjuvant Gemcitabine and Cisplatin in Cisplatin-Eligible Participants With Muscle-Invasive Bladder Cancer Keynote-B15 , Ev-304 · 2023Their institution$320,541
Seagen Inc. · A Dose-Escalation and Dose-Expansion Study of Enfortumab Vedotin (Asg-22ce) in Combination With Pembrolizumab and/Or Chemotherapy for Treatment of Patients With Locally Advanced Or Metastatic Urothelial Cancer · 2020Their institution$301,624
Regeneron Pharmaceuticals, Inc. · Phase 1/2 Study of Regn4336 (A Psmaxcd3 Bispecific Antibody) Administered Alone Or in Combination With Cemiplimab in Patients With Metastatic Castration-Resistant Prostate Cancer · 2023Their institution$298,122
Seagen Inc. · A Dose-Escalation and Dose-Expansion Study of Enfortumab Vedotin (Asg-22ce) in Combination With Pembrolizumab and/Or Chemotherapy for Treatment of Patients With Locally Advanced Or Metastatic Urothelial Cancer · 2023Their institution$282,043
JAZZ PHARMACEUTICALS INC. · Emerge-201: A Phase 2, Multicenter, Open-Label Study of Lurbinectedin Efficacy and Safety in Participants With Advanced Or Metastatic Solid Tumors · 2023Their institution$265,255
Merck Sharp & Dohme LLC · A Phase 3, Randomized, Open-Label Study To Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab Mk-3475 Versus Neoadjuvant Gemcitabine and Cisplatin in Cisplatin-Eligible Participants With Muscle-Invasive Bladder Cancer Keynote-B15 , Ev-304 · 2024Their institution$250,092
AstraZeneca Pharmaceuticals LP · Neoadjuvant Durvalumab and Chemotherapy in Variant Histology Muscle Invasive Bladder Cancer · 2019Their institution$237,932
Seattle Genetics, Inc. · A Dose-Escalation and Dose-Expansion Study of Enfortumab Vedotin Asg-22ce in Combination With Pembrolizumab Andor Chemotherapy for Treatment of Patients With Locally Advanced Or Metastatic Urothelial Cancer · 2019Their institution$230,446
JAZZ PHARMACEUTICALS INC. · Emerge-201: A Phase 2, Multicenter, Open-Label Study of Lurbinectedin Efficacy and Safety in Participants With Advanced Or Metastatic Solid Tumors · 2024Their institution$213,197
Seagen Inc. · A Dose-Escalation and Dose-Expansion Study of Enfortumab Vedotin (Asg-22ce) in Combination With Pembrolizumab and/Or Chemotherapy for Treatment of Patients With Locally Advanced Or Metastatic Urothelial Cancer · 2021Their institution$208,761
Merck Sharp & Dohme LLC · A Phase 3, Randomized, Open-Label Study To Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab Mk-3475 Versus Neoadjuvant Gemcitabine and Cisplatin in Cisplatin-Eligible Participants With Muscle-Invasive Bladder Cancer Keynote-B15 , Ev-304 · 2022Their institution$183,398
AstraZeneca Pharmaceuticals LP · A Phase III, Randomized, Open-Label, Multi-Center, Global Study To Determine the Efficacy and Safety of Durvalumab in Combination With Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed By Durvalumab Alone for Adjuvant Treatment in Patients With Muscle-Invasive Bladder Cancer · 2020Their institution$177,979
Merck Sharp & Dohme LLC · A Multi-Center, Double-Blind, Randomized Phase 3 Study To Compare the Efficacy and Safety of Belzutifan Mk-6482 Plus Pembrolizumab Mk- 3475 Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma Ccrcc Post Nephrectomy 6482-022 · 2022Their institution$174,217
Celgene Corporation · Ph I Fih Mcrpc Mono Cc-94676-Pca-001 - A Phase 1, Multi-Center, Open-Label, Dose Finding Study To Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Cc-94676 in Subjects With Metastatic Castration-Resistant Prostate Cancer · 2024Their institution$166,717
Regeneron Pharmaceuticals, Inc. · Phase 1/2 Study of Regn4336 (A Psmaxcd3 Bispecific Antibody) Administered Alone Or in Combination With Cemiplimab in Patients With Metastatic Castration-Resistant Prostate Cancer · 2024Their institution$163,965
Merck Sharp & Dohme LLC · A Phase 3, Randomized, Open-Label Study of Mk-5684 Versus Alternative Abiraterone Acetate Or Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer Mcrpc That Progressed on Or After Prior Treatment With One Next Generation Hor · 2025Their institution$159,386
AstraZeneca Pharmaceuticals LP · A Phase III, Randomized, Open-Label, Multi-Center, Global Study To Determine the Efficacy and Safety of Durvalumab in Combination With Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed By Durvalumab Alone for Adjuvant Treatment in Patients With Muscle-Invasive Bladder Cancer · 2021Their institution$149,507
PFIZER INC. · A Phase 3 Randomized Doubleblind Placebocontrolled Study of Talazoparib in Combination With Physicians Choice of Enzalutamide Or Abiraterone Acetateprednisone in Metastatic Castrationresistant Prostate Cancer With Dna Damage Repair Deficiencies · 2020Their institution$147,057
Eisai Inc. · A Multicenter, Open-Label, Randomized, Phase 3 Trial To Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus Or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma · 2019Their institution$141,188
Exelixis Inc. · A Phase 1b Dose Escalation Study of Cabozantinib (Xl184) Administered Alone Or in Combination With Atezolizumab To Subjects With Locally Advanced Or Metastatic Solid Tumors · 2024Their institution$137,269
Merck Sharp & Dohme LLC · A Phase 3, Randomized, Open-Label Study To Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab Mk-3475 Versus Neoadjuvant Gemcitabine and Cisplatin in Cisplatin-Eligible Participants With Muscle-Invasive Bladder Cancer Keynote-B15 , Ev-304 · 2025Their institution$131,522
Exelixis Inc. · A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (Xl184) in Combination With Atezolizumab Vs Second Novel Hormonal Therapy (Nht) in Subjects With Metastatic Castration-Resistant Prostate Cancer · 2023Their institution$128,256
Exelixis Inc. · Study of Cabozantinib in Combination With Atezolizumab To Subjects With Locally Advanced Or Metastatic Solid Tumors · 2019Their institution$122,979
Bayer HealthCare Pharmaceuticals Inc. · Bay 1841788, Mhspc · 2022Their institution$114,932
E.R. Squibb & Sons, L.L.C. · A Phase 1, Multi-Center, Open-Label, Dose Finding Study To Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Cc-94676 in Subjects With Metastatic Castration-Resistant Prostate Cancer · 2025Their institution$112,756
Exelixis Inc. · A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of Xl092 in Subjects With Inoperable Locally Advanced Or Metastatic Solid Tumors · 2024Their institution$108,812
Exelixis Inc. · A Randomized, Open-Label, Controlled Study of Cabozantinib (Xl184) in Combination With Atezolizumab Vs Second Novel Hormonal Therapy (Nht) in Subjects With High-Risk, Metastatic Castration-Resistant Prostate Cancer · 2025Their institution$102,656
Merck Sharp & Dohme Corporation · A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (Mk-3475) As Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy · 2019Their institution$97,477
Astellas Pharma Global Development · A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of Asg-22ce Given As Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4 · 2020Their institution$96,298
E.R. Squibb & Sons, L.L.C. · Phase III Rcc Monotherapy Vs. Everolimus Ono 4538-03 · 2020Their institution$91,231
Celgene Corporation · A Phase 1, Multi-Center, Open-Label, Dose Finding Study To Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Cc-94676 in Subjects With Metastatic Castration-Resistant Prostate Cancer · 2025Their institution$84,284
Merck Sharp & Dohme Corporation · A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab Mk-3475 As Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy · 2020Their institution$79,880
Seagen Inc. · A Dose-Escalation and Dose-Expansion Study of Enfortumab Vedotin (Asg-22ce) in Combination With Pembrolizumab and/Or Chemotherapy for Treatment of Patients With Locally Advanced Or Metastatic Urothelial Cancer · 2022Their institution$77,706
Exelixis Inc. · A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (Xl184) in Combination With Atezolizumab Vs Second Novel Hormonal Therapy (Nht) in Subjects With Metastatic Castration-Resistant Prostate Cancer · 2022Their institution$76,337
Aveo Pharmaceuticals, Inc. · Tinivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-Label Study To Compare Tivozanib in Combination With Nivolumab To Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One Or Two Lines of Therapy Where One Line Has An Immune Checkpoint Inhibitor · 2023Their institution$75,865
AstraZeneca Pharmaceuticals LP · Neoadjuvant Durvalumab and Chemotherapy in Variant Histology Muscle Invasive Bladder Cancer · 2020Their institution$74,400
Genentech, Inc. · Phase III Ipatasertib Plus Abirateron in Mcrpc 1st Line · 2019Their institution$72,642
Clovis Oncology, Inc. · A Study of Rucaparib in Patients With Metastatic Castration-Resistant Prostate Cancer and Homologous Recombination Gene Deficiency (Triton2) · 2019Their institution$71,291
Regeneron Pharmaceuticals, Inc. · Phase 1/2 Study of Regn4336 (A Psmaxcd3 Bispecific Antibody) Administered Alone Or in Combination With Cemiplimab in Patients With Metastatic Castration-Resistant Prostate Cancer · 2022Their institution$69,283
E.R. Squibb & Sons, L.L.C. · Ph 1 Study in Metastatic Castration-Resistant Prostate Cancer · 2024Their institution$67,489
Genentech, Inc. · Phase III Ipatasertib Plus Abirateron in Mcrpc 1st Line · 2020Their institution$65,583
AstraZeneca Pharmaceuticals LP · Neoadjuvant Durvalumab and Chemotherapy in Variant Histology Muscle Invasive Bladder Cancer · 2022Their institution$56,165
Exelixis Inc. · Study of Cabozantinib in Combination With Atezolizumab To Subjects With Locally Advanced Or Metastatic Solid Tumors · 2022Their institution$51,727
Exelixis Inc. · A Randomized, Open-Label, Controlled Study of Cabozantinib (Xl184) in Combination With Atezolizumab Vs Second Novel Hormonal Therapy (Nht) in Subjects With High-Risk, Metastatic Castration-Resistant Prostate Cancer · 2024Their institution$51,422
E.R. Squibb & Sons, L.L.C. · A Phase 1, Open-Label Study of Bms-986460 in Participants With Metastatic Castration-Resistant Prostate Cancer · 2025Their institution$50,591
AstraZeneca Pharmaceuticals LP · A Phase III, Randomized, Open-Label, Multi-Center, Global Study To Determine the Efficacy and Safety of Durvalumab in Combination With Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed By Durvalumab Alone for Adjuvant Treatment in Patients With Muscle-Invasive Bladder Cancer · 2022Their institution$48,420
AstraZeneca Pharmaceuticals LP · Study of Medi4736 Durvalumab With Or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer · 2019Their institution$40,228
Clovis Oncology, Inc. · A Study of Rucaparib in Patients With Metastatic Castration-Resistant Prostate Cancer and Homologous Recombination Gene Deficiency (Triton2) · 2020Their institution$39,714
Astellas Pharma Global Development · A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of Asg-22ce Given As Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Maligt Solid Tumors That Express Nectin-4 · 2022Their institution$39,142
Merck Sharp & Dohme LLC · A Multicenter, Double-Blind, Randomized Phase 3 Study To Compare the Efficacy and Safety of Belzutifan Mk-6482 Plus Pembrolizumab Mk-3475 Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma Ccrcc Post Neph · 2025Their institution$37,618
AstraZeneca Pharmaceuticals LP · Study of Medi4736 Durvalumab With Or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer · 2020Their institution$35,821
E.R. Squibb & Sons, L.L.C. · Phase III Rcc 1l Combo · 2020Their institution$32,207
Clovis Oncology, Inc. · Rucaparib in Patients With Locally Advanced Or Metastatic Urothelial Carcinoma (Atlas) · 2019Their institution$31,744
Bayer Healthcare Pharmaceuticals Inc. · Bay 1841788, Mhspc · 2023Their institution$30,038
Merck Sharp & Dohme LLC · A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab Mk-3475 As Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy Keynote-564 · 2024Their institution$28,809
Merck Sharp & Dohme Corporation · A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab Mk-3475 As Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy · 2021Their institution$28,401
PFIZER INC. · A Phase 3 Randomized Doubleblind Placebocontrolled Study of Talazoparib With Enzalutamide in Metastatic Castrationresistant Prostate Cancer · 2022Their institution$28,374
E.R. Squibb & Sons, L.L.C. · Ph-2 Dose Range With Population Pk in Rcc · 2024Their institution$28,108
Bayer HealthCare Pharmaceuticals Inc. · Bay 1841788 Mhspc · 2019Their institution$26,797
Janssen Research & Development, LLC · A Phase 2, Two-Arm Multicenter, Open-Label Study To Determine the Efficacy and the Safety of Two Different Dose Regimens of A Pan-Fgfr Tyrosine Kinase Inhibitor Jnj-42756493 in Subjects With Metastatic Or Surgically Unresectable Urothelial Cancer With Fgfr Genomic Alterations · 2019Their institution$26,305
Merck Sharp & Dohme LLC · Mk-5684-003# A Phase 3 Randomized, Open-Label Study of Mk-5684 Versus Alternative Abiraterone Acetate Or Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer Mcrpc Previously Treated With Next-Generation Hormonal Agent Nha · 2025Their institution$25,574
PFIZER INC. · A Phase 3 Randomized Openlabel Study of Pf06821497 Mevrometostat in Combination With Enzalutamide Compared With Enzalutamide Or Docetaxel in Participants With Metastatic Castration Resistant Prostate Cancer Previously Treated With Abiraterone Acetate Mevpro1 · 2025Their institution$25,182
Astellas Pharma Global Development · A Phase 2 Open-Label Extension Study for Subjects With Prostate Cancer Who Previously Participated in An Enzalutamide Clinical Study · 2020Their institution$24,944
Eisai Inc. · A Multicenter, Open-Label, Randomized, Phase 3 Trial To Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus Or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (Clear) · 2023Their institution$24,719
Clovis Oncology, Inc. · A Study of Rucaparib in Patients With Metastatic Castration-Resistant Prostate Cancer and Homologous Recombination Gene Deficiency (Triton2) · 2021Their institution$24,436
E.R. Squibb & Sons, L.L.C. · Ph-2 Dose Range With Population Pk in Rcc · 2021Their institution$24,347
Bayer HealthCare Pharmaceuticals Inc. · Bay 1841788 Mhspc · 2020Their institution$24,201
Bayer HealthCare Pharmaceuticals Inc. · Darolutamide Roll Over Study · 2022Their institution$22,870
Novartis Pharmaceuticals Corporation · A Randomized Double Blind Placebo Controlled Phase III Study To Evaluate the Efficacy and Safety of Pazopanib As Adjuvant Therapy for Subjects With Localized Or Locally Advanced Rcc Following Nephrectomy · 2019Their institution$22,698
AstraZeneca Pharmaceuticals LP · A Phase III, Randomized, Open-Label, Multi-Center, Global Study To Determine the Efficacy and Safety of Durvalumab in Combination With Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed By Durvalumab Alone for Adjuvant Treatment in Patients With Muscle-Invasive Bladder Cancer · 2024Their institution$21,246
E.R. Squibb & Sons, L.L.C. · Phase III Rcc Monotherapy Vs. Everolimus Ono 4538-03 · 2019Their institution$20,318
Merck Sharp & Dohme LLC · A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab Mk-3475 As Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy Keynote-564 · 2022Their institution$19,214
AstraZeneca Pharmaceuticals LP · Study of Medi4736 Durvalumab With Or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer · 2021Their institution$16,094
Merck Sharp & Dohme LLC · A Phase 3 Randomized, Open-Label Study of Mk-5684 Versus Alternative Abiraterone Acetate Or Enzalutamide in Participants With Metastatic Castration Resistant Prostate Cancer Mcrpc Previously Treated With Next-Generation Hormonal Agent Nha and Taxane-Based Chemotherapy. · 2024Their institution$15,840
Genentech, Inc. · Bladder Cancer · 2019Their institution$15,277
Aveo Pharmaceuticals, Inc. · Tinivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-Label Study To Compare Tivozanib in Combination With Nivolumab To Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One Or Two Lines of Therapy Where One Line Has An Immune Checkpoint Inhibitor · 2025Their institution$14,763
Genentech, Inc. · Atezolizumab in Muscle Invasive Bladder Cancer Mibc · 2019Their institution$14,459
Genentech, Inc. · Atezolizumab in Muscle Invasive Bladder Cancer Mibc · 2020Their institution$14,207
Exelixis Inc. · A Phase 1b Dose Escalation Study of Cabozantinib Xl184 Administered Alone Or in Combination With Atezolizumab To Subjects With Locally Advanced Or Metastatic Solid Tumors · 2019Their institution$14,159
Aveo Pharmaceuticals, Inc. · Tinivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-Label Study To Compare Tivozanib in Combination With Nivolumab To Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One Or Two Lines of Therapy Where One Line Has An Immune Checkpoint Inhibitor · 2024Their institution$12,913
E.R. Squibb & Sons, L.L.C. · Ph III Rcc 1l Combo - A Phase 3, Randomized, Open-Label Study of Nivolumab Combined With Ipilimumab Versus Sunitinib Monotherapy in Subjects With Previously Untreated, Advanced Or Metastatic Renal Cell Carcinoma · 2022Their institution$12,160
E.R. Squibb & Sons, L.L.C. · Phase III Rcc 1l Combo · 2019Their institution$12,160
Eisai Inc. · A Multicenter, Open-Label, Randomized, Phase 3 Trial To Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus Or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma · 2020Their institution$12,111
Merck Sharp & Dohme LLC · A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab Mk-3475 As Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy Keynote-564 · 2023Their institution$11,937
PFIZER INC. · A Phase 3 Randomized Doubleblind Placebocontrolled Study of Talazoparib With Enzalutamide in Metastatic Castrationresistant Prostate Cancer · 2021Their institution$11,584
Bayer HealthCare Pharmaceuticals Inc. · Bay 1841788 Mhspc · 2021Their institution$11,396
Genentech, Inc. · Atezolizumab in Muscle Invasive Bladder Cancer Mibc · 2024Their institution$11,125
Janssen Research & Development, LLC · A Phase 2, Two-Arm Multicenter, Open-Label Study To Determine the Efficacy and the Safety of Two Different Dose Regimens of A Pan-Fgfr Tyrosine Kinase Inhibitor Jnj-42756493 in Subjects With Metastatic Or Surgically Unresectable Urothelial Cancer With Fgfr Genomic Alterations · 2020Their institution$10,995
Genentech, Inc. · Phase III Ipatasertib Plus Abiraterone in Mcrpc 1st Line · 2025Their institution$10,560
E.R. Squibb & Sons, L.L.C. · Ph-2 Dose Range With Population Pk in Rcc · 2022Their institution$10,522
Astellas Pharma Global Development · A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of Asg-22ce Given As Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4 · 2021Their institution$9,870
Bayer Healthcare Pharmaceuticals Inc. · Bay 1841788, A Roll-Over Study To Provide Continued Treatment With Darolutamide in Subjects Who Were Entered in Darolutamide Studies · 2025Their institution$9,820
AstraZeneca Pharmaceuticals LP · Neoadjuvant Durvalumab and Chemotherapy in Variant Histology Muscle Invasive Bladder Cancer · 2021Their institution$8,960
E.R. Squibb & Sons, L.L.C. · Ph-2 Dose Range With Population Pk in Rcc · 2020Their institution$7,834
Eisai Inc. · A Multicenter, Open-Label, Randomized, Phase 3 Trial To Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus Or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (Clear) · 2021Their institution$7,292
Exelixis Inc. · Study of Cabozantinib in Combination With Atezolizumab To Subjects With Locally Advanced Or Metastatic Solid Tumors · 2021Their institution$7,177
PFIZER INC. · Enfortumab Vedotin Clinical Publication Program · 2025This clinician$7,140
Eisai Inc. · A Multicenter, Open-Label, Randomized, Phase 3 Trial To Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus Or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (Clear) · 2024Their institution$7,087
PFIZER INC. · A Doseescalation and Doseexpansion Study of Enfortumab Vedotin Asg22ce in Combination With Pembrolizumab Andor Chemotherapy for Treatment of Patients With Locally Advanced Or Metastatic Urothelial Cancer · 2024Their institution$6,788
Exelixis Inc. · A Phase 1b Dose Escalation Study of Cabozantinib (Xl184) Administered Alone Or in Combination With Atezolizumab To Subjects With Locally Advanced Or Metastatic Solid Tumors · 2025Their institution$5,847
Novartis Pharmaceuticals Corporation · Publication Support Provided in Connection With Heor Research · 2022This clinician$5,820
Merck Sharp & Dohme LLC · A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab Mk-3475 As Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy Keynote-564 · 2025Their institution$5,795
AstraZeneca Pharmaceuticals LP · A Phase III, Randomized, Open-Label, Multi-Center, Global Study To Determine the Efficacy and Safety of Durvalumab in Combination With Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed By Durvalumab Alone for Adjuvant Treatment in Patients With Muscle-Invasive Bladder Cancer · 2023Their institution$5,695
PFIZER INC. · Prevail A Multinational Phase 3 Randomized Doubleblind Placebocontrolled Efficacy and Safety Study of Oral Mdv3100 in Chemotherapynaive Patients With Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy · 2020Their institution$5,376
Clovis Oncology, Inc. · Rucaparib in Patients With Locally Advanced Or Metastatic Urothelial Carcinoma (Atlas) · 2020Their institution$5,120
AstraZeneca Pharmaceuticals LP · A Phase III, Randomized, Open-Label, Multi-Center, Global Study To Determine the Efficacy and Safety of Durvalumab in Combination With Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed By Durvalumab Alone for Adjuvant Treatment in Patients With Muscle-Invasive Bladder Cancer · 2025Their institution$4,897
Genentech, Inc. · Bladder Cancer · 2024Their institution$4,480
E.R. Squibb & Sons, L.L.C. · Phase III Rcc 1l Combo - A Phase 3, Randomized, Open-Label Study of Nivolumab Combined With Ipilimumab Versus Sunitinib Monotherapy in Subjects With Previously Untreated, Advanced Or Metastatic Renal Cell Carcinoma · 2022Their institution$3,565
Bayer Healthcare Pharmaceuticals Inc. · Darolutamide Roll Over Study · 2023Their institution$3,465
E.R. Squibb & Sons, L.L.C. · Phase III Rcc Monotherapy Vs. Everolimus Ono 4538-03 · 2021Their institution$3,232
Bayer Healthcare Pharmaceuticals Inc. · An Open-Label, Single Arm, Roll-Over Study To Provide Continued Treatment With Darolutamide in Participants Who Were Enrolled in Previous Bayer-Sponsored Studies · 2025Their institution$2,780
AstraZeneca Pharmaceuticals LP · Study of Medi4736 Durvalumab With Or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer · 2022Their institution$2,629
Bayer Healthcare Pharmaceuticals Inc. · Bay 1841788, A Randomized, Doubleblind, Placebocontrolled Phase III Study of Darolutamide (Odm201) Versus Placebo in Addition To Standard Androgen Deprivation Therapy and Docetaxel in Patients With Metastatic Hormonesensitive Prostate Cancer · 2024Their institution$2,560
Astellas Pharma Global Development · A Phase 2 Open-Label Extension Study for Subjects With Prostate Cancer Who Previously Participated in An Enzalutamide Clinical Study · 2019Their institution$2,515
Astellas Pharma Global Development · A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of Asg-22ce Given As Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4 · 2023Their institution$2,355
Astellas Pharma Global Development · A Phase 2 Open-Label Extension Study for Subjects With Prostate Cancer Who Previously Participated in An Enzalutamide Clinical Study · 2022Their institution$2,256
E.R. Squibb & Sons, L.L.C. · Phase III Rcc Monotherapy Vs. Everolimus Ono 4538-03 - A Randomized, Open-Label, Phase 3 Study of Bms-936558 Vs. Everolimus in Subjects With Advanced Or Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy · 2022Their institution$2,240
E.R. Squibb & Sons, L.L.C. · Phase III Rcc 1l Combo - A Phase 3, Randomized, Open-Label Study of Nivolumab Combined With Ipilimumab Versus Sunitinib Monotherapy in Subjects With Previously Untreated, Advanced Or Metastatic Renal Cell Carcinoma · 2023Their institution$1,410
Merck Sharp & Dohme Corporation · A Multi-Center, Double-Blind, Randomized Phase 3 Study To Compare the Efficacy and Safety of Belzutifan Mk-6482 Plus Pembrolizumab Mk- 3475 Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma Ccrcc Post Nephrectomy 6482-022 · 2021Their institution$1,116
PFIZER INC. · Padcev Clinical Publication Program · 2024This clinician$940
E.R. Squibb & Sons, L.L.C. · Phase III Rcc Monotherapy Vs. Everolimus (Ono 4538-03) - A Randomized, Open-Label, Phase 3 Study of Bms-936558 Vs. Everolimus in Subjects With Advanced Or Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy · 2023Their institution$896
Astellas Pharma Global Development · A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of Asg-22ce Given As Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4 · 2020This clinician$853
Merck Sharp & Dohme LLC · Open Label Ph III Study of Belzu Zanza 1l Post Io in Arcc · 2024Their institution$616
Genentech, Inc. · Bladder Cancer · 2025Their institution$599
Merck Sharp & Dohme LLC · A Phase 3, Randomized, Double-Blind, Study of Belzutifan Zanzalintinib Versus Belzutifan Placebo in Participants With Advanced Rcc Who Have Progressed on Or After Both Pd-1,L1 and Vegf-Tki Therapies in Sequence Or in Combination Litespark-034 · 2024Their institution$561
Regeneron Pharmaceuticals, Inc. · Phase 1/2 Study of Regn4336 (A Psmaxcd3 Bispecific Antibody) Administered Alone Or in Combination With Cemiplimab in Patients With Metastatic Castration-Resistant Prostate Cancer · 2025This clinician$485
E.R. Squibb & Sons, L.L.C. · Phase III Rcc 1l Combo · 2021Their institution$470
Eisai Inc. · A Multicenter, Open-Label, Randomized, Phase 3 Trial To Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus Or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (Clear) · 2022Their institution$448
Merck Sharp & Dohme Corporation · Pembrolizumab in Muscle Invasive and Locally Advanced Urothelial Carcinoma Ambassador · 2019Their institution$342
JAZZ PHARMACEUTICALS INC. · Emerge-201: A Phase 2, Multicenter, Open-Label Study of Lurbinectedin Efficacy and Safety in Participants With Advanced Or Metastatic Solid Tumors · 2025Their institution$272
Regeneron Pharmaceuticals, Inc. · Phase 1/2 Study of Regn4336 (A Psmaxcd3 Bispecific Antibody) Administered Alone Or in Combination With Cemiplimab in Patients With Metastatic Castration-Resistant Prostate Cancer · 2024This clinician$234
JAZZ PHARMACEUTICALS INC. · Emerge-201: A Phase 2 Multicenter Open-Label Study of Lurbinectedin Efficacy and Safety in Participants With Advanced Or Metastatic Solid Tumors · 2022Their institution$224
Astellas Pharma Global Development · Asp1941 Phase II Clinical Study A Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Response Study in Patients With Type 2 Diabetes Mellitus · 2020This clinician$171
Corcept Therapeutics · Cort125134-551 · 2021This clinician$40

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score
76.5 / 100
Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI
1205913589
Licence
CA A49392California A49392: Current · expires 2027-03-31
Video visits
Lists video visits
Gender
Female
More record details
Sole proprietor
No
Taxonomy
Medical oncology (207RX0202X)
Mailing address
300 Pasteur Dr, Stanford, CA, 94305
NPI first listed
2006-11-01
NPI last updated
2024-04-12
NPI record certified
2024-04-12

This is when the NPI record was last certified, not a medical board exam.